Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Total Liabilities: 2012-2025

Historic Total Liabilities for Ptc Therapeutics (PTCT) over the last 13 years, with Sep 2025 value amounting to $2.8 billion.

  • Ptc Therapeutics' Total Liabilities fell 3.35% to $2.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 billion, marking a year-over-year decrease of 3.35%. This contributed to the annual value of $2.8 billion for FY2024, which is 3.27% up from last year.
  • As of Q3 2025, Ptc Therapeutics' Total Liabilities stood at $2.8 billion, which was down 1.45% from $2.8 billion recorded in Q2 2025.
  • Over the past 5 years, Ptc Therapeutics' Total Liabilities peaked at $2.9 billion during Q3 2024, and registered a low of $1.8 billion during Q3 2022.
  • For the 3-year period, Ptc Therapeutics' Total Liabilities averaged around $2.6 billion, with its median value being $2.8 billion (2025).
  • Per our database at Business Quant, Ptc Therapeutics' Total Liabilities spiked by 105.95% in 2021 and then fell by 5.21% in 2022.
  • Quarterly analysis of 5 years shows Ptc Therapeutics' Total Liabilities stood at $1.9 billion in 2021, then rose by 5.99% to $2.1 billion in 2022, then skyrocketed by 32.23% to $2.7 billion in 2023, then grew by 3.27% to $2.8 billion in 2024, then fell by 3.35% to $2.8 billion in 2025.
  • Its last three reported values are $2.8 billion in Q3 2025, $2.8 billion for Q2 2025, and $2.8 billion during Q1 2025.